Centre for Biocatalytic Manufacture of New Modalities (CBNM)

在不断发展的医药和疾病治疗领域，人们正在确定新的、更具挑战性的药物靶点，这需要更复杂的药物分子。这些复杂分子或“新模式”弥补了现有两类化合物，小分子（如阿司匹林）和生物制剂（抗体）之间的差距，通常比现有的小分子大，但比传统生物制剂小。这些新型分子为新疗法提供了巨大的希望，事实上，许多这些药物针对的是传统小分子或抗体衍生药物无法解决的生物靶点。新模式的复杂性目前导致制造成本高，这为开发低成本的路线来生产这些化合物提供了机会。小分子制造商受益于在制造策略中采用生物催化，并已证明这些催化剂在更广泛的化学制造中使用的潜力，例如减少废物流，降低能源成本和降低包括溶剂在内的商品成本。事实上，项目合作伙伴已经进行了一些早期的概念验证研究，并得到了更广泛的文献证据基础的支持，这些文献证据表明，生物催化可以用于这些新模式的合成。通过与曼彻斯特大学、阿斯利康和Prozomix的合作，我们汇集了各种各样的专家，他们将促进新的制造战略的发展，以更高效、更清洁的方式生产这些新模式。生物催化的使用有可能使制药制造界无法获得的化学物质和生产控制成为可能。最终导致生产成本降低，这意味着更广泛的社区更容易获得下一代药物。

In the ever developing world of pharmaceuticals and treatments of diseases new, more challenging drug targets are being identified that require ever more complex drug molecules. These complex molecules or "New Modalities" bridge the gap between the two existing classes of compounds, small molecules (e.g. Aspirin) and biologics (Antibodies), and are typically larger than the existing small molecules but smaller than traditional biologics. These new classes of molecule offer great promise as novel therapies and indeed many of these medicines are aimed at biological targets that cannot be addressed by traditional either small molecule or antibody derived drugs. The complexity of the new modalities currently results in high cost of manufacture which offers an opportunity to develop lower cost routes to produce these compounds. Small molecule manufacturer has benefited from adopting biocatalysis within manufacturing strategies and has demonstrated the potential for use of these catalysts in wider chemical manufacture, such as reduced waste streams, lower energy costs and reduced costs of goods including solvents. Indeed, the project partners have already generated some early proof-of-concept studies, backed up by a wider literature evidence base suggesting that biocatalysis can be used in the synthesis of these new modalities.Through the partnership of the University of Manchester, AstraZeneca and Prozomix we are bringing together a diverse range of experts that will facilitate the development of new manufacturing strategies to produce these new modalities in an efficient and cleaner manner. The use of biocatalysis has the potential to allow access to chemistries and control of manufacture that are otherwise unavailable to the pharmaceutical manufacturing community. Culminating in lower cost manufacturing that translates into greater access to the next generation of drug for a wider community.